Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646693 | 0.86 | — | — | |
| SCHEMBL1244011 | 0.80 | ALDH1A1 (0.34) | EPHX1ALDH1A1 | |
| SCHEMBL22814668 | 0.77 | — | — | |
| SCHEMBL20477531 | 0.74 | EPHX1 (0.41) | EPHX1ALDH1A1USP2ALOX15TDP1 | |
| SCHEMBL7278841 | 0.74 | — | — | |
| SCHEMBL11286201 | 0.74 | — | — | |
| SCHEMBL5408963 | 0.69 | ALDH1A1 (0.54) | EPHX1ALDH1A1USP2ALOX15TDP1 | |
| SCHEMBL9213351 | 0.68 | ALDH1A1 (0.57) | EPHX1ALDH1A1USP2ALOX15TDP1 | |
| SCHEMBL9209673 | 0.68 | ALDH1A1 (0.57) | EPHX1ALDH1A1USP2ALOX15TDP1 | |
| SCHEMBL11788866 | 0.68 | ALDH1A1 (0.57) | EPHX1ALDH1A1USP2ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108084083-A | Synthesis method of N-substituent-1, 2,3, 6-tetrahydropyridine | 中山市得高行知识产权中心（有限合伙） | 2018-05-29 | — | — | CN | disclosed |
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | disclosed |
| US-8829041-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8592467-B2 | Benzothiazole cyclobutyl amine derivatives | ABBVIE INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2386556-B1 | Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands | ABBVIE INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8399468-B2 | Octahydro-pyrrolo[3,4-B]pyrrole derivatives | ABBOTT LABORATORIES (US) | 2013-03-19 | — | — | US | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1926729-B1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
| CN-1120167-C | Tetrahydropyridine-(or 4-hydroxypiperidine) Alkylazoles having an affinity for sigma and/or 5HTIA receptors | ESTEVE S A LAB DE DR (ES) | 2003-09-03 | — | — | CN | disclosed |
| EP-0721455-B1 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | ESTEVE LABOR DR (ES) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002068388-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| CN-1166173-A | Tetrahydropyridine- (or 4-hydroxypiperidine) alkylpyrroles active at sigma and/or 5HTIA receptors | ESTEVE S A LAB DE DR (ES) | 1997-11-26 | — | — | CN | disclosed |
| EP-0721455-A1 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996004287-A1 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| CN-1034922-A | The tetrahydropyridine derivatives preparation method | RICHTER GEDEON VEGYESZET (HU) | 1989-08-23 | — | — | CN | disclosed |
| US-4277608-A | Method of preparing 4a-arylhexahydro-1H-2-pyrindines and 4a-aryloctahydroisoquinolines | ELI LILLY AND COMPANY (US) | 1981-07-07 | — | — | US | disclosed |
| US-4236009-A | Method of preparing 4A-arylhexahydro-1H-2-pyrindines and 4A-aryloctahydroisoquinolines | ELI LILLY AND COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | EPHX1 3724/4885ALDH1A1 2626/4885USP2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.